New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is ...

"BridgeBio’s stock up as muscular dystrophy therapy meets Phase III endpoints" was originally created and published by ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

Learn how Duchenne muscular dystrophy affects oral health and explore tips for daily care, dental visits, and preventing ...

Five-year follow-up data for Santhera Pharmaceuticals AG’s Duchenne muscular dystrophy (DMD) drug, Agamree (vamorolone), confirm that its efficacy in preserving muscle function is comparable to ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Shares of BridgeBio Pharma rose after the company reported positive data in the phase three study of its treatment of limb-girdle muscular dystrophy. The stock rose 10% to $59.74 in premarket trading ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

Find out how many sit-ups after 55 signal a strong, healthy core and use this 60-second test to track your strength over time.

The major resemblance between teeth and bones is what they're made of: hard tissue composed of minerals, such as calcium, ...